As per top corporate executive, Novo Nordisk India Pvt. Ltd, the local affiliate of Danish pharmaceutical multinational Novo Nordisk, is in early talks with Torrent Pharmaceuticals Ltd to expand their manufacturing partnership. “It is a formidable partnership," managing director Vikrant Shrotriya said, noting it has stood the test of time over three decades. “I believe they have been a very reliable partner. So, we have been evaluating on expanding our partnership with them," Shrotriya said in an interview. “We are considering whether this (existing capacity) is sufficient. Probably, there is time before we might be working on an expansion," he said.
However, Shrotriya did not share any details on the ongoing discussions. Torrent Pharmaceuticals now manufactures insulin for Novo Nordisk in Gujarat using crystals sourced from Denmark. Discussions have started at a time the company is looking to launch its weight-loss drug, Wegovy, in India by 2026. The companies have initiated the pre-launch process, including applying for regulatory approvals as per livemint.
“There are always plans, and we are trying it as early as possible. We are working to create the pre-launch processes in terms of creating awareness. We are building capacity and working with doctors to create awareness, working on training courses, so that they understand obesity better," he said. “Once we are done with awareness, and penetrating India’s insulin market, we will be finalizing obesity product launches as well." Wegovy made its debut in the United States in 2021 and was afterwards launched in several European nations, including the United Kingdom. The business claimed that it might not introduce the medicine in underdeveloped countries since it couldn't match demand in rich countries.
, CDSCO.jpg)
.jpg)